🧪 Biotechnology: Historical Timeline & Scientific Milestones

Isolated the first site-specific restriction endonuclease (HindII) from Haemophilus influenzae that recognizes and cleaves double-stranded DNA at a specific symmetric nucleotide sequence (1978 Nobel Prize).

Synthesized the first artificial recombinant DNA molecule by joining DNA from SV40 virus with bacteriophage lambda using EcoRI and DNA ligase (1980 Nobel Prize).

Engineered the pSC101 plasmid vector with foreign antibiotic-resistance genes, transformed competent calcium chloride-treated E. coli, and demonstrated stable replication and functional expression in living bacteria.

140 molecular biologists from around the world convened to voluntarily establish biological and physical containment standards (P1 to P4 levels) for conducting recombinant DNA experiments safely.

Fused short-lived normal antibody-producing spleen B cells with immortal HGPRT-deficient myeloma cells using polyethylene glycol (PEG), creating hybridomas that secrete unlimited identical monoclonal antibodies (1984 Nobel Prize).

Venture capitalist Robert Swanson and scientist Herbert Boyer founded Genentech ('Genetic Engineering Technology'), the world's first dedicated recombinant DNA commercial enterprise.

Maxam and Gilbert developed chemical cleavage DNA sequencing; Sanger invented the enzymatic dideoxy chain-termination method using 2',3'-ddNTPs (1980 Nobel Prize).

Synthesized artificial genes encoding the separate A and B chains of human insulin, expressed them as beta-galactosidase fusions in E. coli, cleaved them with cyanogen bromide, and joined them via in vitro disulfide oxidation.

The U.S. Supreme Court ruled in a landmark 5–4 decision that genetically engineered living microorganisms (a hydrocarbon-degrading Pseudomonas bacterium engineered with four plasmids) are patentable subject matter.

The U.S. Food and Drug Administration (FDA) approved Humulin (recombinant human insulin), the first medicine produced via recombinant DNA technology cleared for clinical human administration.

Conceived the cyclic thermal enzymatic reaction utilizing two synthetic oligonucleotide primers flanking a target sequence, amplifying specific DNA sequences a billion-fold in hours (1993 Nobel Prize).

Disarmed the tumor-inducing (Ti) plasmid of Agrobacterium tumefaciens by replacing oncogenes with antibiotic-resistance genes, generating the first genetically engineered transgenic tobacco plants.

Discovered that human genomes contain hypervariable tandem repetitive minisatellites (VNTRs), developing multi-locus Southern blot probe profiles unique to every individual on Earth.

Invented the biolistic particle delivery system ('gene gun'), coating microscopic gold or tungsten microprojectiles with plasmid DNA and accelerating them with pressurized helium pulses through plant cell walls.

Treated 4-year-old Ashanti DeSilva, who suffered from Adenosine Deaminase-deficient Severe Combined Immunodeficiency (ADA-SCID), by extracting her T cells, transducing them with a retroviral vector carrying normal ADA cDNA, and re-infusing them.

The FDA approved the Flavr Savr tomato, engineered with an antisense gene blocking polygalacturonase (a pectin-degrading ripening enzyme), allowing tomatoes to ripen on the vine with prolonged shelf life.

Cloned Dolly the Sheep by transferring a quiescent nucleus from an adult mammary epithelial cell of a 6-year-old ewe into an enucleated oocyte, proving adult mammalian somatic cell differentiation is reversible.

Approved Rituximab (Rituxan), a chimeric mouse/human IgG1 monoclonal antibody directed against the CD20 surface antigen on B cells, for the treatment of refractory B-cell non-Hodgkin lymphoma.

Approved Trastuzumab, a recombinant humanized monoclonal antibody targeting the extracellular domain of the HER2/neu receptor tyrosine kinase, for metastatic breast cancer overexpressing HER2.

Engineered the provitamin A (beta-carotene) biosynthetic pathway into rice endosperm by introducing phytoene synthase (psy from daffodil) and carotene desaturase (crtI from Erwinia uredovora).

Announced the finished reference sequence of the 3-billion-base human genome, revealing ~20,000–25,000 protein-coding genes and establishing open genomic data access for global science.

Commercialized sequencing-by-synthesis on planar flow cells using reversible dye terminators and clonal bridge PCR amplification (acquired by Illumina in 2007).

Chemically synthesized the 1.08-million-base pair chromosome of Mycoplasma mycoides from digitized computer code and transplanted it into a recipient Mycoplasma capricolum cell, creating the first self-replicating synthetic organism.

Re-engineered bacterial Cas9 nuclease into a two-component programmable system using a single-guide RNA (sgRNA) to execute site-specific double-strand breaks at any targeted DNA locus (2020 Nobel Prize).

Approved Tisagenlecleucel (Kymriah), an autologous CAR-T cell therapy for relapsed/refractory pediatric B-cell acute lymphoblastic leukemia (ALL), achieving an 83% complete remission rate.

Developed and gained emergency authorization for BNT162b2 and mRNA-1273 in under 11 months, delivering modified synthetic mRNA encapsulated in lipid nanoparticles to elicit neutralizing immunity against SARS-CoV-2 (2023 Nobel Prize).

Approved by UK MHRA and US FDA: Casgevy (Exagamglogene autotemcel), the world's first medicine utilizing CRISPR-Cas9 genome editing, curatively treating sickle cell disease and transfusion-dependent beta-thalassemia.

Used deep learning diffusion models (RFdiffusion) to computationally design entirely de novo synthetic proteins, custom vaccine nanoparticles, and targeted picomolar cancer receptor binders from scratch (2024 Nobel Prize).